My wish for our type A meeting ...
I am still supremely confident that Mesoblast will eventually start getting ticks & approvals from the fda...
my hope for this meeting is that whilst
1. providing the extra data which proves the stock of remestemcel-L for commercialisation is the the same or very similar to the cells that were provided in our recent trials..
2. we go into this meeting with a back up , with adults trials ready to go ( in short course )
I hope that our trials begin very soon , because wether we can or cannot prove/ convince the fda with the new potency data presented that we deserve an Accelerated Approval ... then at least we are already moving forward towards a rapid outcome from a short trial to finally get us Full Approval ...
mesoblast deserves a break and the kids and adults with SR aGVHD deserve a break we the long term holders deserve a break...
It gives me great confidence that the CEO , CMO and board of directors have all agreed to substantial cuts to their fees and instead they will be receiving Long Term Incentives ... I like this!!!
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-16799
-
- There are more pages in this discussion • 1,140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $1.087B |
Open | High | Low | Value | Volume |
98.0¢ | 98.5¢ | 95.0¢ | $1.978M | 2.049M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 35670 | 95.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
96.0¢ | 63727 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 14172 | 0.955 |
21 | 104529 | 0.950 |
19 | 250762 | 0.945 |
18 | 289023 | 0.940 |
12 | 332620 | 0.935 |
Price($) | Vol. | No. |
---|---|---|
0.960 | 66018 | 21 |
0.965 | 115275 | 18 |
0.970 | 176956 | 16 |
0.975 | 180164 | 11 |
0.980 | 218794 | 8 |
Last trade - 14.04pm 13/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online